| Identification | Back Directory | [Name]
PantoprazoleSodiumSesquihydrate | [CAS]
164579-32-2 | [Synonyms]
Unii-6871619Q5x
BY1023 (sodium hydrate)
SKF-96022 SODIUM HYDRATE
Pantoprazole sodium hydrate
Pantoprazole sodium sesquihydrate CRS
Pantoprazole for system suitability CRS
Pantoprazole Sodium sesqui hydrate- IP/BP/USP
6-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt hydrate (2:2:3)
1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-, sodium salt, hydrate (2:3)
Pantoprazole Sodium SesquihydrateQ: What is
Pantoprazole Sodium Sesquihydrate Q: What is the CAS Number of
Pantoprazole Sodium Sesquihydrate Q: What is the storage condition of
Pantoprazole Sodium Sesquihydrate | [EINECS(EC#)]
1312995-182-4 | [Molecular Formula]
C16H15F2N3O4S.3/2H2O.Na | [MDL Number]
MFCD16879010 | [MOL File]
164579-32-2.mol | [Molecular Weight]
864.75 |
| Chemical Properties | Back Directory | [Appearance]
White or almost white powder. | [storage temp. ]
4°C, protect from light | [solubility ]
Freely soluble in water and in ethanol (96 per cent), practically insoluble in hexane. | [form ]
neat | [color ]
White to off-white |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white powder. | [Uses]
Treatment of various acid-related gastrointestinal diseases, including acute erosive esophagitishealing and maintenance, treatment of hypersecretory
conditions, Zollinger-Ellison Syndrome (ZES), and eradication
of Helicobacter pylori infection. | [Brand name]
Protonix (Wyeth). | [in vivo]
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin[1].
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats[4].
| Animal Model: | Mice bearing MCF-7 or A431 xenografts[1] | | Dosage: | 200 mg/kg | | Administration: | IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.) | | Result: | Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin.
There is no effect on growth delay alone.
|
|
|
|